PMGC Holdings (ELAB) Exchange Rate Effect (2022 - 2026)
PMGC Holdings (ELAB) posted Exchange Rate Effect of $2339.0 for Q1 2026, up 464.98% sequentially from $414.0 in Q4 2025, and up 598.72% YoY from $334.75 in Q1 2025.
PMGC Holdings (ELAB) Exchange Rate Effect (2022 - 2026) Analysis & Trends
PMGC Holdings has reported Exchange Rate Effect for 5 years, with the latest figure at $2339.0 in Q1 2026.
- Quarterly Exchange Rate Effect rose 598.72% year-over-year to $2339.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2985.0 (up 199.6% YoY) and the FY2025 annual result came in at $177.0, up 107.52% from the prior year.
- Exchange Rate Effect rose to $2339.0 in Q1 2026 per ELAB's latest filing, from $414.0 in the prior quarter.
- Over five years, Exchange Rate Effect peaked at $1.1 million in Q4 2022 and troughed at -$1587.0 in Q4 2024.
- A 5-year average of $78850.8 and a median of $152.0 in 2023 frame the typical range for Exchange Rate Effect.
- The sharpest annual moves came in 2024 and 2026: Exchange Rate Effect plunged 2237.5% in 2024, then jumped 598.72% in 2026.
- Over 5 years, Exchange Rate Effect stood at $1.1 million in 2022, then sank by 99.97% to $342.0 in 2023, then plunged by 564.04% to -$1587.0 in 2024, then jumped by 126.09% to $414.0 in 2025, then surged by 464.98% to $2339.0 in 2026.
- According to Business Quant data, Exchange Rate Effect over the past three periods registered $2339.0, $414.0, and $163.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -2.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.84 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -2.45 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -287,000.00 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.63 Mn |
| 10 | PMGC Holdings | 3.01 Mn | -15.78 Mn | 385,691.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,339.00 |
| Mar 31, 2026 | 2,339.00 |
| Dec 31, 2025 | 414.00 |
| Dec 31, 2025 | 414.00 |
| Sep 30, 2025 | 163.00 |
| Sep 30, 2025 | 163.00 |
| Jun 30, 2025 | 69.00 |
| Jun 30, 2025 | 69.00 |
| Mar 31, 2025 | -469.00 |
| Mar 31, 2025 | -469.00 |
| Dec 31, 2024 | -1,587.00 |
| Dec 31, 2024 | -1,587.00 |
| Sep 30, 2024 | -187.00 |
| Sep 30, 2024 | -187.00 |
| Jun 30, 2024 | -754.00 |
| Jun 30, 2024 | -754.00 |
| Mar 31, 2024 | 174.00 |
| Mar 31, 2024 | 174.00 |
| Dec 31, 2023 | 342.00 |
| Dec 31, 2023 | 342.00 |